MTOR and metabolic dysfunction-associated steatotic liver disease: Additionally, GCDA regulates the activity of the PI3K/AKT/mTOR pathway by increasing the expression level of S1PR2, thus promoting the onset and progression of NAFLD-HCC and enhancing the malignant biological activity of HCC cells.